New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans ...

Almost three-fourths of patients with biochemically recurrent prostate cancer remained metastasis free at 5 years following ...

New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from ...

Commonwealth Health Wilkes-Barre General Hospital is the first institution in our area to offer the new FDA approved and NCCN-indicated, prostate specific membrane antigen (PSMA) imaging agent to ...

A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center and published in ...

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Bone scans have been found to overstage prostate cancer at initial staging compared to prostate-specific membrane antigen (PSMA) PET, according to new research published in the November issue of the ...

Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

For generations, medical students were taught that the map of the human body was essentially complete. Yet cancer imaging has ...

Figure 1. A 74-y-old man at initial staging with PSMA PET that demonstrates low uptake in primary tumor (A, arrowhead) and left pelvic side wall node (A, arrow). Bone scan was read as positive by 2 of ...